<DOC>
	<DOCNO>NCT00803374</DOCNO>
	<brief_summary>The purpose study determine BMS-663513 administered combination ipilimumab patient advance malignant melanoma safe tolerable</brief_summary>
	<brief_title>Combination Anti-CD137 &amp; Ipilimumab Patients With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm malignant melanoma Stage III ( unresectable ) Stage IV disease may treat one prior cytotoxic chemotherapy and/or 3 therapeutic regimen Willing undergo 3 biopsy accessible lesion Active/symptomatic brain metastasis Primary ocular melanoma primary tumor unknown origin Concurrent autoimmune disease Previous treatment CD137 agonist CTLA4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>